Skip to content
Home/Companies/Biotech/PinCell
PinCell

PinCell

Biotech·Italy·Exited 2025·Held 6yr
Entry
2019
Hold
6yr
Exit
2025

Who owns PinCell?

PinCell is an Italian Biotech company, now owned by Scinai Immunotherapeutics, which acquired it in 2025 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital IX · 2018 · Life Sciences VC

Key facts

HQItaly
SectorBiotech
Websitewww.pincell.it
Exit Type
Trade Sale
Buyer
Scinai Immunotherapeutics
Exit Year
2025

More from Sofinnova Capital IX

Other portfolio companies in the same fund.

Asceneuron
Active
BiotechSwitzerland· 2020
CorVent Medical
CorVent Medical
Active
MedTechUS· 2020
Genespire
Genespire
Active
BiotechItaly· 2020
Nitrase Therapeutics
Nitrase Therapeutics
Active
BiotechUS· 2020
Noema Pharma
Noema Pharma
Exited 2022
BiotechSwitzerland· 2020
to NOEMA PHARMA SA
Pi-Cardia
Pi-Cardia
Active
MedTechIsrael· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns PinCell?

PinCell is now owned by Scinai Immunotherapeutics, which acquired it in 2025 from Sofinnova Partners.

When did Scinai Immunotherapeutics acquire PinCell?

Scinai Immunotherapeutics acquired PinCell in 2025, buying from Sofinnova Partners.

Who did PinCell sell to?

Sofinnova Partners sold PinCell to Scinai Immunotherapeutics in 2025 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue